The Eukaryotic Transcriptional Regulation Section in the Mouse Cancer Genetics Program at CCR, NCI, seeks a highly motivated postdoctoral researcher to participate in a project exploring mechanisms that control cellular responses to oncogenic RAS signaling. The project focuses on the novel role of 3’UTRs in regulating phosphorylation/activation of the encoded proteins by oncogenic kinases such as ERK1/2 and CK2. The mechanism involves mRNA partitioning, in part through localized, 3’UTR-mediated mRNA decay adjacent to perinuclear kinases in tumor cells. Our research is highly interdisciplinary and intersects the fields of RNA biology, signaling and cancer biology. Talented individuals who wish to pursue an independent research track will have the opportunity to develop their own projects toward the end of their training period.
Detailed information on the lab’s current research can be found at https://ccr.cancer.gov/staff-directory/peter-f-johnson
For a list of lab publications, please click on the link below:
Salotti, J. et al.: 3'UTR-directed, kinase proximal mRNA decay inhibits C/EBPb phosphorylation/activation to suppress senescence in tumor cells. https://doi.org/10.1101/2022.03.29.486281
Hu, L. et al.: 3'UTR-dependent dynamic changes in TP53 mRNA localization regulate p53 tumor suppressor activity. https://doi.org/10.1101/2022.04.04.487038
Basu, S. et al.: CK2 signaling from TOLLIP-dependent perinuclear endosomes is an essential feature of KRAS mutant cancers. https://doi.org/10.1101/2022.04.05.487175
The Mouse Cancer Genetics Program offers a challenging, stimulating and collaborative research environment and training opportunities to postdoctoral fellows. The position is available immediately.
Qualifications and Job Details
Required and Preferred Skills
Candidates should have a rigorous background in molecular/cellular biology, with experience in RNA biology strongly preferred. Good oral and written communication skills are required.
Applicants must have a Ph.D. and/or M.D. or equivalent degree and should have less than one year of postdoctoral experience.
About the NCI Center for Cancer Research
The Center for Cancer Research (CCR) is home to nearly 250 basic and clinical research groups located on two campuses just outside of Washington, D.C. CCR is part of the National Cancer Institute (NCI) and makes up the largest component of the research effort at the National Institutes of Health (NIH). Centrally supported by long-term funding and a culture of complete intellectual freedom, CCR scientists are able to pursue the most important and challenging problems in cancer research. We collaborate with academic and commercial partners and advocacy groups across the world in efforts to prevent, diagnose and treat cancer and HIV/AIDS. The CCR research portfolio covers the full spectrum of biological and biomedical research. Our work ranges from basic to translational and clinical, and our clinical trials are conducted in the NIH Clinical Center, the world’s largest hospital dedicated to clinical research that offers a robust infrastructure to support CCR’s patients on an estimated 250 open studies. The success of CCR is grounded in an exceptionally strong discovery research program that provides the foundation for the seamless translation of insights from bench to bedside. Read more about CCR, the benefits of working at CCR and hear from our staff on their CCR experiences.
Frederick is the second largest city in Maryland but retains a “small town” feel, surrounded by mountain views with a vibrant Main Street community. The city offers outstanding schools, a balanced and thriving economy and a highly educated workforce.